Effectiveness and safety assessment of add-on therapy of perampanel for epilepsy patients

Effectiveness and safety assessment of add-on therapy of perampanel for epilepsy patients - Effectiveness and safety assessment of add-on therapy of perampanel for epilepsy patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026880

Enrollment

100

Registered

2017-04-06

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy syndromes

Interventions

Administration of perampanel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed as epilepsy syndrome with partial epilepsy 2. A patient treating with one anti-epileptic drug

Exclusion criteria

Exclusion criteria: 1. Pregnancy patient 2. Simple partial seizure patient 3. Psychiatric unstable patient 4. Liver dysfunction patient 5. Alcoholic patient 6. Surgically treated patient

Design outcomes

Primary

Measure	Time frame
Change of seizure frequency. The number of seizure attack every 2 weeks will be monitored.	—

Secondary

Measure	Time frame
A complete seizure reduction ratio, 50% reduction ratio, tolerability and EEG	—

Countries

Japan

Contacts

Public ContactNoboru Yoshida

Juntendo University Nerima Hospital Pediatrics Division

noyoshi@juntendo.ac.jp03-5923-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026